Table 3.

CNV Treatment Methods in Group 1 & 2.

Methods	Patients (N = 30)
Intravitreal anti-VEGF injection, n (%) (mean)	22 (73.3) (4.9)
Bevacizumab, n	14
Ranibizumab, n	5
Aflibercept, n	1
Bevacizumab + Ranibizumab, n	1
Bevacizumab + Ranibizumab + Aflibercept, n	1
PDT + intravitreal anti-VEGF injection, n (%)	5 (16.7)
Bevacizumab + PDT, n	3
Bevacizumab + Ranibizumab + PDT, n	2
PDT, n (%)	1 (3.3)
Surgery*, n (%)	1 (3.3)
No treatment, n (%)	1 (3.3)

VEGF = vascular endothelial growth factor; PDT = photodynamic therapy.

Group 1: Patients with secondary CNV in eyes with previous CSC.

Group 2: Patients diagnosed with CNV in eyes with putative chronic CSC beforehand.

*Pars plana vitrectomy, removal of subretinal membrane.